In more than thirty years as a CEO and senior leader in the pharmaceutical industry, Pedro Lichtinger has dealt with the risk, cost, and time associated with researching and developing new medicines. Seeing Starton’s proprietary transdermal technology, Pedro recognized the opportunity to transform standard-of-care therapies and transform the management of hematological cancer into that of chronic disease. 

As the CEO and Chairman at Starton, Pedro leads a team of some of the brightest and most experienced minds in clinical development and hematology/oncology, who have joined the Board, raised their hands, and committed their experience to change the fate of people struggling with the impact of their disease. 

You can learn more and connect with Pedro Lichtinger on the links below.

• Website - https://www.startontx.com/
• LinkedIn - https://www.linkedin.com/in/pedro-lichtinger-47286617/

YouTube: https://www.youtube.com/channel/UC4XCvuwxnFi5_7C6Ncm12xQ

LinkedIn: https://www.linkedin.com/company/success-fundamentals™

Facebook: https://www.facebook.com/successfundamentalspodcast

Instagram : https://instagram.com/successfundamentalspodcast?utm_medium=copy_link